CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic ...
Phase 3
Cleveland, Ohio, United States and 37 other locations
objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic...
Phase 3
Cleveland, Ohio, United States and 230 other locations
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL...
Phase 1, Phase 2
Cleveland, Ohio, United States and 79 other locations
This phase I trial studies the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia...
Phase 1
Cleveland, Ohio, United States and 11 other locations
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with...
Phase 1
Cleveland, Ohio, United States and 40 other locations
This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolera...
Phase 1, Phase 2
Cleveland, Ohio, United States and 55 other locations
A phase 1/2a, first-in-human trial to evaluate the safety and tolerability of LAVA-051 in patients with relapsed or refractory Chronic Lymphocytic...
Phase 1, Phase 2
Cleveland, Ohio, United States and 13 other locations
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients wi...
Phase 1
Cleveland, Ohio, United States and 24 other locations
in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) or B cell acute lympho...
Phase 1
Cleveland, Ohio, United States and 6 other locations
Assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) / recommended phase 2 dose...
Phase 1
Cleveland, Ohio, United States and 8 other locations
Clinical trials
Research sites
Resources
Legal